BioSpace News Archive

Two separate analyses point to difficulties biosimilar manufacturers have had in carving out market share of branded drugs.

A recent study found that combining a well-known breast cancer drug with a lung cancer drug, at least in cells in the laboratory, was significantly more effective in killing cancer cells.

The new strategy uses the deactivated Cas13 enzyme to guide RESCUE to targeted cytosine bases on RNA transcripts.

As the beta-amyloid theory of Alzheimer’s disease fades from prominence, many researchers are turning their attention to the role of inflammation. Although beta-amyloid is still very much a factor in the disease, many believe that it is an uncontrolled or faulty inflammatory and immune reaction to beta-amyloid that causes the majority of the cognitive damage.

It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.

David Lickrish took time to speak with BioSpace about the companies’ new drug, Jornay PM (methylphenidate HCL Extended-Release CLL Capsules), and how it fits into the overall ADHD therapeutic market.